Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Home-based cardio-oncology rehabilitation using a telerehabilitation platform in hematological cancer survivors: a feasibility study

K. Filakova, A. Janikova, M. Felsoci, F. Dosbaba, JJ. Su, G. Pepera, L. Batalik

. 2023 ; 15 (1) : 38. [pub] 20230323

Status not-indexed Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23002640

PURPOSE: Cardiovascular disease is a competing mortality cause in hematological cancer survivors due to toxic oncological treatment, accumulation of risk factors, and decline of cardiorespiratory fitness. Cardio-oncology rehabilitation (CORE) is an emerging treatment model to optimize the prognosis of hematological cancer patients and survivors; however, its accessibility during the COVID-19 pandemic is poor. The study aimed to evaluate the feasibility, safety, and effect of a 12-week home-based CORE intervention in telerehabilitation approach among hematological cancer survivors. METHODS: A prospective single-arm interventional study was conducted at a faculty hospital in Brno, Czech Republic. This study provided 12 weeks of the home-based CORE using a telerehabilitation approach that allows remote supervision by a clinician from a medical facility. The telerehabilitation approach consists of three components: a heart rate sensor (PolarM430, Kempele, Finland), a web platform compatible with the sensor, and telesupervising via telephone call (1 call per week). To improve adherence, a physiotherapist called participants to assess or address adverse effects, exercise feedback, and participant-related concerns. The anthropometry, body composition, and cardiorespiratory fitness were measured immediately after the intervention. RESULTS: Eleven hematological cancer survivors with an average age of 60.3 ± 10 years participated in the study. Most participants were diagnosed with Follicular lymphoma and received maintenance treatment. Participants had a significant (p < 0.05) increase in cardiorespiratory fitness by 2.6 ml/kg/min; and in peak workload, from 143.3 ± 60.6 W to 158.6 ± 67.5 W (p < 0.05). Improvement in anthropometry and body composition was observed but yielded no statistical significance. Most (80%) participants completed the three times/per week telesupervising exercise session for 12 weeks.No adverse event was identified. CONCLUSION: Findings from this study suggest that home-based CORE may provide hematological cancer survivors with an increase in CRF during the rehabilitation period after hospital discharge. The telerehabilitation CORE model is effective, feasible, safe, and has demonstrated good adherence. Further randomized controlled efficacy study with larger sample size is needed before clinical implementation. CLINICAL TRIAL REGISTRATION: Clinical trial registration number NCT04822389 (30/03/2021).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23002640
003      
CZ-PrNML
005      
20230421100146.0
007      
ta
008      
230413s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13102-023-00650-2 $2 doi
035    __
$a (PubMed)36959613
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Filakova, Katerina $u Department of Rehabilitation, University Hospital Brno, Brno, Czech Republic $u Department of Rehabilitation and Sports Medicine, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000242023564
245    10
$a Home-based cardio-oncology rehabilitation using a telerehabilitation platform in hematological cancer survivors: a feasibility study / $c K. Filakova, A. Janikova, M. Felsoci, F. Dosbaba, JJ. Su, G. Pepera, L. Batalik
520    9_
$a PURPOSE: Cardiovascular disease is a competing mortality cause in hematological cancer survivors due to toxic oncological treatment, accumulation of risk factors, and decline of cardiorespiratory fitness. Cardio-oncology rehabilitation (CORE) is an emerging treatment model to optimize the prognosis of hematological cancer patients and survivors; however, its accessibility during the COVID-19 pandemic is poor. The study aimed to evaluate the feasibility, safety, and effect of a 12-week home-based CORE intervention in telerehabilitation approach among hematological cancer survivors. METHODS: A prospective single-arm interventional study was conducted at a faculty hospital in Brno, Czech Republic. This study provided 12 weeks of the home-based CORE using a telerehabilitation approach that allows remote supervision by a clinician from a medical facility. The telerehabilitation approach consists of three components: a heart rate sensor (PolarM430, Kempele, Finland), a web platform compatible with the sensor, and telesupervising via telephone call (1 call per week). To improve adherence, a physiotherapist called participants to assess or address adverse effects, exercise feedback, and participant-related concerns. The anthropometry, body composition, and cardiorespiratory fitness were measured immediately after the intervention. RESULTS: Eleven hematological cancer survivors with an average age of 60.3 ± 10 years participated in the study. Most participants were diagnosed with Follicular lymphoma and received maintenance treatment. Participants had a significant (p < 0.05) increase in cardiorespiratory fitness by 2.6 ml/kg/min; and in peak workload, from 143.3 ± 60.6 W to 158.6 ± 67.5 W (p < 0.05). Improvement in anthropometry and body composition was observed but yielded no statistical significance. Most (80%) participants completed the three times/per week telesupervising exercise session for 12 weeks.No adverse event was identified. CONCLUSION: Findings from this study suggest that home-based CORE may provide hematological cancer survivors with an increase in CRF during the rehabilitation period after hospital discharge. The telerehabilitation CORE model is effective, feasible, safe, and has demonstrated good adherence. Further randomized controlled efficacy study with larger sample size is needed before clinical implementation. CLINICAL TRIAL REGISTRATION: Clinical trial registration number NCT04822389 (30/03/2021).
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Janikova, Andrea $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/0000000226477769 $7 xx0103433
700    1_
$a Felsoci, Marian $u Department of Internal Medicine and Cardiology, University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/0000000238290467
700    1_
$a Dosbaba, Filip $u Department of Rehabilitation, University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/0000000281051744
700    1_
$a Su, Jing Jing $u School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China $1 https://orcid.org/000000028242811X
700    1_
$a Pepera, Garyfallia $u Clinical Exercise Physiology and Rehabilitation Research Laboratory, Physiotherapy Department, School of Health Sciences, University of Thessaly, Lamia, Greece $1 https://orcid.org/0000000180120325
700    1_
$a Batalik, Ladislav $u Department of Rehabilitation, University Hospital Brno, Brno, Czech Republic. batalik.ladislav@fnbrno.cz $u Department of Public Health, Faculty of Medicine, Masaryk University, Brno, Czech Republic. batalik.ladislav@fnbrno.cz $1 https://orcid.org/0000000321471541
773    0_
$w MED00208616 $t BMC sports science, medicine & rehabilitation $x 2052-1847 $g Roč. 15, č. 1 (2023), s. 38
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36959613 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230413 $b ABA008
991    __
$a 20230421100139 $b ABA008
999    __
$a ok $b bmc $g 1922621 $s 1188847
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 15 $c 1 $d 38 $e 20230323 $i 2052-1847 $m BMC sports science, medicine & rehabilitation $n BMC Sports Sci Med Rehabil $x MED00208616
LZP    __
$a Pubmed-20230413

Find record

Citation metrics

Archiving options